4.8 Article

A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells

Journal

CELL
Volume 184, Issue 3, Pages 792-+

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2021.01.010

Keywords

-

Funding

  1. National Natural Science Foundation of China [81988101, 91742203, 91942307, 31991171]
  2. Beijing Municipal Science and Technology Commission [Z201100005320014]
  3. Beijing Advanced Innovation Center for Genomics
  4. AOSpine 2019 Discovery and Innovation Award [AOSDIA2019-026]
  5. Beijing Natural Science Foundation [7204327]

Ask authors/readers for more resources

This study conducted a pan-cancer analysis of single myeloid cells from 210 patients across 15 human cancer types, revealing distinct features of TIMs in different cancer types. For example, mast cells in nasopharyngeal cancer were associated with better prognosis, and pro-angiogenic TAMs showed diverse markers across different cancer types. The composition of TIMs appeared to be linked with certain features of somatic mutations and gene expressions.
Tumor-infiltrating myeloid cells (TIMs) are key regulators in tumor progression, but the similarity and distinction of their fundamental properties across different tumors remain elusive. Here, by performing a pan-cancer analysis of single myeloid cells from 210 patients across 15 human cancer types, we identified distinct features of TIMs across cancer types. Mast cells in nasopharyngeal cancer were found to be associated with better prognosis and exhibited an anti-tumor phenotype with a high ratio of TNF+/VEGFA(+) cells. Systematic comparison between cDC1- and cDC2-derived LAMP3(+) cDCs revealed their differences in transcription factors and external stimulus. Additionally, pro-angiogenic tumor-associated macrophages (TAMs) were characterized with diverse markers across different cancer types, and the composition of TIMs appeared to be associated with certain features of somatic mutations and gene expressions. Our results provide a systematic view of the highly heterogeneous TIMs and suggest future avenues for rational, targeted immunotherapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available